Cargando…

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis

BACKGROUND: There is marked interindividual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosis treatment. For isoniazid, mutations in the N-acetyltransferase 2 (NAT2) gene explain >88% of pharmacokinetic variability. However, weight-based dosing rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rens, Neil E, Uyl-de Groot, Carin A, Goldhaber-Fiebert, Jeremy D, Croda, Julio, Andrews, Jason R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819527/ https://www.ncbi.nlm.nih.gov/pubmed/31905381 http://dx.doi.org/10.1093/cid/ciz1212

Ejemplares similares

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis( )
por: McCallum, Andrew D, et al.
Publicado: (2022)

Tuberculosis in prison inmates in Southern Brazil: investigating the epidemiological and operational indicators
por: Busatto, Caroline, et al.
Publicado: (2022)

Delay in the diagnosis and treatment of tuberculosis in prisons in Mato Grosso do Sul, Brazil
por: Ribeiro, Carla Celina, et al.
Publicado: (2023)

Estimating the cost of cervical cancer screening in five developing countries
por: Goldhaber-Fiebert, Jeremy D, et al.
Publicado: (2006)

Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study
por: Chin, Elizabeth T, et al.
Publicado: (2022)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India
por: Subbaraman, Ramnath, et al.
Publicado: (2021)

Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis
por: Goldhaber-Fiebert, Jeremy D., et al.
Publicado: (2023)

Dose of Isoniazid in Renal Disease for Treatment of Tuberculosis
por: Sarma, G. R. K.
Publicado: (2022)

Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)
por: De Castro, N, et al.
Publicado: (2022)

Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
por: Cipriano, Lauren E., et al.
Publicado: (2018)

Whole-genome Sequencing Provides Data for Stratifying Infection Prevention and Control Management of Nosocomial Influenza A
por: Roy, Sunando, et al.
Publicado: (2019)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Disease Control Implications of India's Changing Multi-Drug Resistant Tuberculosis Epidemic
por: Suen, Sze-chuan, et al.
Publicado: (2014)

Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar
por: Malloy, Giovanni S. P., et al.
Publicado: (2021)

Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings
por: Gupta, Amita, et al.
Publicado: (2022)

Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda
por: Forman, Leah S, et al.
Publicado: (2022)

Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis
por: Claypool, Anneke L., et al.
Publicado: (2021)

Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients
por: Liu, Shan, et al.
Publicado: (2011)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Public Health Impact and Cost-Effectiveness of Screening for Active Tuberculosis Disease or Infection Among Children in South Africa
por: Brough, Joseph, et al.
Publicado: (2023)

Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India’s public care system covering >100,000,000 inhabitants
por: Babiarz, Kimberly S, et al.
Publicado: (2014)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

NAT2 Genotype and Isoniazid Medication in Children
por: Golka, Klaus, et al.
Publicado: (2016)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Is there a role of pharmacogenomics in Africa
por: Matimba, A., et al.
Publicado: (2016)

Pharmacogenomics of inhalational anesthetic agents
por: Nair, Abhijit S.
Publicado: (2019)

Challenges and Opportunities in Pharmacogenomics and Therapeutics
por: Kane, Michael D., et al.
Publicado: (2007)

Providers' knowledge of diagnosis and treatment of tuberculosis using vignettes: evidence from rural Bihar, India
por: Mohanan, Manoj, et al.
Publicado: (2016)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing
por: Verma, Renu, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States
por: Liu, Shan, et al.
Publicado: (2013)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Cost-effectiveness of Xpert(®)MTB/RIF in the diagnosis of tuberculosis: pragmatic study
por: da Silva, Suely Conceição Alves, et al.
Publicado: (2021)

Delayed Tuberculosis Treatment and Cost of Care in a Low-Incidence Country
por: O’Connell, James, et al.
Publicado: (2022)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7e255rssn7v1l74grbnrn51h10